Drug Profile
AMB 051
Alternative Names: AMB 053; AMB-051; AMB-055; AMB-05X; AMG-820Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; AmMax Bio; LifeMax Laboratories
- Class Antibodies; Antifibrotics; Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Urologics
- Mechanism of Action Macrophage colony stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Giant cell tumour of tendon sheath; Idiopathic pulmonary fibrosis
- Phase I/II Solid tumours
- Preclinical Autosomal recessive polycystic kidney disease; Diabetic macular oedema; Unspecified; Wet age-related macular degeneration
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Giant-cell-tumour-of-tendon-sheath in USA (IV)
- 30 Jan 2023 AmMax Bio plans a phase III trial for Tenosynovial Giant Cell Tumor
- 26 Jan 2023 Phase-II clinical trials in Giant cell tumour of tendon sheath in Australia (Intra-articular) (NCT05349643)